Clinical Trials Logo

Coronary Disease clinical trials

View clinical trials related to Coronary Disease.

Filter by:

NCT ID: NCT02145481 Completed - Clinical trials for Coronary Artery Disease

Decisional Quality for Patients With Coronary Artery Disease

DeQCAD
Start date: May 1, 2014
Phase: N/A
Study type: Interventional

The objective of the DeQCAD study is to measure the quality of the decision-making process for patients with coronary artery disease (CAD) and Acute Coronary Syndrome (ACS) who are making treatment decisions. In particular, this study is seeking to answer: a) How informed are patients about their treatment choices, b) are patients participating in the decision-making process as much as they would like to, and c) do the treatment decisions made match patients' preferences?

NCT ID: NCT02144480 Completed - Clinical trials for Coronary Artery Disease

Efficacy of Early Short-term Training on Thrombogenesis in Patients Following Coronary Bypass Surgery

Start date: October 2013
Phase: N/A
Study type: Interventional

Although the benefit of cardiac rehabilitation following coronary artery bypass graft (CABG) is well-established, it is underused. The current investigation will adopt an early, intensive, short-term and supervised aerobic training at moderate-intensity. The inclusion criteria are diagnosed coronary artery disease (CAD) and clinical indication for elective first-time CABG. Regular physical exercise is associated with overall reduced risk of primary cardiac arrest. Previous study demonstrated that moderate-intensity exercise training reduced resting and strenuous exercise-induced activation of platelet and possibly coagulation. Our main research question is that whether the short-term CR program in the present investigation will ameliorate hemostatic imbalance at rest and platelet coagulation activation at maximal stress exercise. This is designed to be a prospective randomized controlled study. Sixty men who are scheduled to receive elective CABG in Chang Gung Memorial Hospital at Linkuo will be enrolled in the study. They will be randomized into two groups: intensive training (IT) and usual rehabilitation (UR). Participants in the IT group will receive intensive aerobic training at moderate intensity after CABG. A submaximal exercise test will be performed for intensity prescription. They will receive two training sessions per day and at least 20 sessions in total. The CR group will receive usual CR program. After intervention, each participant will receive a maximal exercise test. Additionally, six-minute walk test, generic and disease-specific quality of life, will be collected before and after training. Additional 20 age-matched non-sedentary and healthy men without training will be recruited as control group. Venous blood will be sampled three times (before and after rehabilitation and maximal stress test) for the assessment of platelet activation by flow cytometer and activity of coagulation factors. Mean platelet volume, and platelet activation markers (platelet-bound CD62P%G, CD63%G, CD40L%G) will be analyzed. Various coagulation and fibrinolysis factors will be quantified. We hypothesized that this training program will ameliorate the prothrombotic state and attenuate platelet reactivity and coagulation induced by strenuous exercise in patients after CABG. Hopefully, this clinical investigation will establish an early short-term rehabilitation model following CABG and its efficacy for clinical use.

NCT ID: NCT02138006 Completed - Stroke Clinical Trials

Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes

SDIS
Start date: September 1982
Phase: N/A
Study type: Observational

To investigate long-term effects on cardiovascular mortality/morbidity and renal failure in type 1 diabetes patients former randomized to intensive insulin treatment

NCT ID: NCT02137980 Completed - Clinical trials for Coronary Artery Disease

Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site

CPORT
Start date: April 1, 2011
Phase:
Study type: Observational [Patient Registry]

This is a simple registry of patients undergoing PCI at hospitals without surgery on-site who were participants in the CPORT-E project. The aim of the registry is simple data collection and reporting to respective State Departments of Health. The registry population consists of patients undergoing diagnostic cardiac catheterization for suspected CAD at hospitals without SOS and who require PCI.

NCT ID: NCT02137421 Completed - Clinical trials for Coronary Artery Disease

A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome

Start date: April 2012
Phase: N/A
Study type: Interventional

The aim of this study is to explore the role of Canonical β-catenin/Wnt and forkhead box O (FOXO) pathways by means of investigating their target genes in coronary artery disease (CAD) pathogenesis and to examine the effects of resveratrol (RES) on these pathways in CAD patients.

NCT ID: NCT02135939 Completed - Clinical trials for Coronary Artery Disease

Vegan vs AHA Diet on Inflammation and Glucometabolic Profile in Patients With CAD

Start date: March 11, 2014
Phase: N/A
Study type: Interventional

In this randomized study the investigators aim to determine the effects of a whole-food plant-based vegan diet on markers of inflammation and glucometabolic profile in patients with cardiovascular disease. The investigators hypothesize that a whole-food plant-based vegan diet will reduce markers of inflammation and improve glucometabolic profile compared with the American Heart Association (AHA)- recommended diet at 2 months follow-up in patients with coronary artery disease (CAD). The investigators are also evaluating endothelial function using the EndoPAT device and stool microbiome.

NCT ID: NCT02133807 Completed - Atherosclerosis Clinical Trials

Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis

LaRCA
Start date: September 2009
Phase: Phase 3
Study type: Interventional

To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a) levels.

NCT ID: NCT02131935 Completed - Clinical trials for Coronary Artery Disease

Impaired Peripheral Endothelial Function and In-stent Restenosis

Start date: January 2010
Phase: N/A
Study type: Observational [Patient Registry]

The investigators assessed the hypothesis that whether RH-PAT index (RHI) as a marker of endothelial dysfunction could predict occurrence of ISR after percutaneous coronary intervention (PCI).

NCT ID: NCT02127177 Completed - Clinical trials for Obstructive Sleep Apnea

Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients

Start date: January 2010
Phase: N/A
Study type: Interventional

The increased risk of atherosclerotic morbidity and mortality in patients with obstructive sleep apnea (OSA) has been linked to hypertension, insulin resistance, dyslipidemia, and systemic inflammation. The relationship regarding obstructive sleep apnea (OSA) and lipidemia and systemic inflammation is far from conclusion for obesity as a strong confounding factor.

NCT ID: NCT02126982 Completed - Clinical trials for Coronary Artery Disease

Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence

SCIENCE
Start date: October 2012
Phase:
Study type: Observational

Clopidogrel besylate (CB) is not differentiated relative to the orignal clopidogrel hydrogen sulfate (CHS) in the pharmacokinetics and in antiplatelet potency in healthy volunteers. In addition,CB exhibits similar pharmacodynamic properties compared to CHS in patients with a history of acute coronary syndrome (ACS) and in patients with ACS undergoing percutaneous coronary intervention (PCI). However, there is a lack of data on the clinical efficacy and safety of this salt to the original salt in patients with cardiovascular disease. The aim of this study is to investigate the clinical efficacy and safety of CB in relation to that of CHS in patients eligible to receive clopidogrel.